Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)

Next Previous
Trial Profile

A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mazindol (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors NLS Pharma Ltd

    • Most Recent Events

    • 19 Mar 2018 Results (n=85) assessing evaluate the efficacy of mazindol CR in adults with ADHD, were published in the CNS Drugs.
    • 31 Oct 2017 According to an NLS Pharma media release, new data from this trial will be presented at the 2017 American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting and at 2018 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
    • 31 May 2017 Results (n= 85) from this study published in a NLS Pharma Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top